Valeant Takes Allergan Offer To Shareholders In Push To Get A Deal Done
This article was originally published in The Pink Sheet Daily
Valeant set out to control the story line around its drawn-out hostile bid for Allergan, which has raised questions about Valeant’s alternative business model, during a conference call June 17.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.